secwatch.observer — SEC 8-K summary
======================================

Issuer:     COMPASS Pathways plc (CMPS)
CIK:        0001816590
Form:       8-K
Filed at:   2026-03-24T23:59:59+00:00
Accession:  0001816590-26-000021
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Compass Pathways 2025 net loss $287.9M; COMP360 NDA submission on track for Q4 2026
--------------------------------------------------------------------------------

- Full-year 2025 net loss $287.9M ($3.08/share), vs $155.1M in 2024; includes $122.6M non-cash loss on warrant liabilities.
- Q4 2025 net loss $93.9M ($1.00/share), vs $43.3M in Q4 2024.
- COMP360 in TRD: highly statistically significant Phase 3 results; FDA meeting to confirm rolling NDA submission, expected completion in Q4 2026.
- Phase 2b/3 trial in PTSD initiated after FDA acceptance of IND.
- Cash $149.6M at Dec 31, 2025; $150M Feb financing plus $200M warrant exercise extends cash runway into 2028.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1816590/000181659026000021/0001816590-26-000021-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1816590/000181659026000021/cmps-20260324.htm
  HTML page:      https://secwatch.observer/filing/0001816590-26-000021

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer